| Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition | Ismail JATOI | 189–193 |
| QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer | Seigo NAKAMURA, Sadako AKASHI TANAKA, Terumasa SAWADA, Takashi KUWAYAMA, Satoko HANDA, Yasuhisa KATO, Hiromi OKUYAMA | 194–198 |
| Evaluation of Breast Cancer (BC) Awareness among Female University Students in Zarqa University, Jordan | Ashraf KANAN | 199–204 |
| The Effect on Quality of Life and Body Image of Mastectomy Among Breast Cancer Survivors | Meryem YILMAZ, Kübra ERTURHAN TÜRK | 205–210 |
| The Impact of Subtype Distribution in Inflammatory Breast Cancer Outcome | Burcu ÇAKAR, Bülent KARABULUT, Ruchan USLU, Zeki SÜRMELİ, Pınar GÜRSOY ÖNER, Elif Sıla YELİM | 211–217 |
| The Significance of Extent of Extracapsular Extension in Patients with T1-2 and N1 Breast Cancer | Berrin BENLİ YAVUZ, Sıddıka FINDIK, Meryem AKTAN, Gül KANYILMAZ | 218–224 |
| Impact of The Method of Diagnosis on The Stage of Breast Carcinoma | Aylin ERDİM, A. Özdemir AKTAN, Derya ZIVALI, Gülce KAYIKÇI, Selin DOĞU, Gizem PEHLİVAN | 225–228 |
| Bilateral Inflammatory Pseudotumour of the Breast: A Case Report and Review of the Literature | Mohsin DANI, Ian FENTIMAN, Sarah PINDER | 229–233 |
| Dermatofibrosarcoma of The Breast – Case Report and Review of Literature | Amr MUHAMMED, Esraa ELNAKIB, Mahmoud NADY | 234–237 |
| Excisional Biopsies for Diagnosis and Treatment of Breast Lumps in Nigerian Women | David O. IRABOR, Oluwole G. AJAO | 238–238 |